Jasper Therapeutics (NASDAQ:JSPR) Stock Rated “Outperform” in New Coverage at William Blair

William Blair initiated coverage on shares of Jasper Therapeutics (NASDAQ:JSPR) in a report issued on Wednesday, MarketBeat Ratings reports. The brokerage issued an outperform rating on the stock.

Several other equities research analysts also recently commented on the stock. HC Wainwright reaffirmed a “buy” rating on shares of Jasper Therapeutics in a report on Tuesday, August 18th. Piper Sandler initiated coverage on shares of Jasper Therapeutics in a research report on Wednesday, August 12th. They set an “overweight” rating and a $2.00 target price for the company. Wall Street Zen lowered shares of Jasper Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, September 19th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Jasper Therapeutics in a research note on Friday, July 17th. Four analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $7.33.

Jasper Therapeutics Trading Down 9.8%

Jasper Therapeutics stock opened at $0.48 on Wednesday. The business’s 50 day simple moving average is $0.66 and its 200 day simple moving average is $0.69. Jasper Therapeutics has a 12 month low of $0.32 and a 12 month high of $2.69. The company has a market cap of $15.97 million, a price-to-earnings ratio of -0.30 and a beta of 3.16.

Jasper Therapeutics (NASDAQ:JSPR) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.17. As a group, equities research analysts forecast that Jasper Therapeutics will post -0.94 earnings per share for the current fiscal year.

About Jasper Therapeutics

Jasper Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody-based therapies for diseases involving the hematopoietic system, including conditions that require the replacement or modification of blood-forming stem cells. The company’s approach is designed to address biological barriers that can limit stem-cell transplantation, gene therapy and the treatment of mast cell–driven diseases.

Jasper’s lead product candidate is briquilimab, formerly known as JSP191, an investigational monoclonal antibody that targets CD117, a receptor found on hematopoietic stem cells and mast cells.